Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

Inpatient Resource Utilization Outcomes Among Patients Living with Fragile X Syndrome and Comorbid Autism Spectrum Disorder in the US

Speaker(s)

Clark LA1, Banuelos RC2, Belk K3, Rizzo E4
1Lumen Value & Access, New York City, NY, USA, 2Lumen Value & Access, Houston, TX, USA, 3Lumen Value & Access, Mooresville, NC, USA, 4Lumen Value & Access, AKRON, OH, USA

Introduction

Fragile X Syndrome (FXS) is the most common heritable cause of autism and intellectual disability. Autism Spectrum Disorder (ASD) is characterized by social interaction and communication impairment. Individuals with FXS and ASD have greater prevalence of seizures, persistence of sleep problems, and increased behavior problems.

Objective Examine inpatient resource utilization in FXS-diagnosed patients with and without ASD.

Methods

Healthcare Cost and Utilization Project Nationwide Inpatient Sample (2016-2019) data were used to assess encounters aged 1+ years old having ICD-10-CM diagnosis of FXS. Length of stay (LOS), in-hospital mortality and cost-to-charge ratio adjusted charges (costs) were stratified by ASD and compared using chi-square and t-tests. Sampling-weighted logistic regression analyses were used to estimate ASD impact on mortality while hierarchical models were used for LOS and .

Results

The nationally-weighted sample included 6,235 encounters with median (IQR) age of 20 (11-36) years for those with FXS-ASD and 37 (28-59) years for those without ASD. Admissions with FXS-ASD were more likely to be male patients (85.9% vs 49.7%, p<.0001). Medicaid coverage was more common among admissions with FXS-ASD (43.7% vs 25.4%; p<0.001). FSX-ASD admissions were more likely to include neurologic and neuromuscular chronic conditions (28.1% vs 15.8%, p<0.001) but less likely to include chronic cardiovascular conditions (6.0% vs 16.3%, p=0.0002).

Univariate analyses revealed no statistical differences in mortality between encounters with (2.0%) and without (1.8%) ASD. After controlling for other factors, ASD was associated with increased mortality risk (OR=2.33, p=0.0025).

Median LOS (3.0 vs 2.5 days) and median costs ($8,081 vs 6,305) were higher in FXS-ASD however, these differences were not statistically . Multivariate analyses showed no significant differences in LOS (IRR=1.09, CI=0.96-1.23) or costs (IRR=1.15, CI=0.99-1.34).

Conclusion

Among FSX admissions, ASD was associated with higher mortality risk but no differences in LOS or costs compared to admissions without ASD.

Code

RWD48

Topic

Clinical Outcomes

Topic Subcategory

Clinical Outcomes Assessment

Disease

No Additional Disease & Conditions/Specialized Treatment Areas